Pharmaceutical Care for Diabetes type 2 in 28 EU countries: An update of the last decade

---

Angela Pizarro

New University of Lisbon, Portugal

: Endocrinol Diabetes Res

Abstract

---

The collaboration of community pharmacies with primary health care networks to supporting demand for type 2 diabetes mellitus (DM2) is urgent. The analysis of European health systems intervention for DM2 eradication in the last decade points to an insufficient combination of prevention, early diagnosis and outcome sets pharmacotherapeutic- monitoring of the disease. One of the possible solutions to this public health’s problem has proved to be the inclusion of pharmacy services DM2-oriented (PS-DM2) in strategic primary care health programs, provided by the community pharmacist. However, considering that the normative framework of good pharmacy practices and clinical orientations/ guidelines for DM2 from each 28 EU country may represent a limitation to this extension of the community pharmacist’s role, it is necessary to analyze the structure of this new generation of pharmacy services at a regional (EU) and local (EU28) level, in terms of type, of protocols/ guidelines for their practice and of legal framework, in order to assess their evolution throughout time. The present study proposed a qualitative approach about the recent phenomenon of PS- DM2 in EU28 over the last decade.

Recent Publications

1. Tamayo T, Rosenbauer J, Wild S, Apijkerman A, Baan C, Forouhi N, et al. Diabetes in Europe: An update. Diabetes research and clinical practice. 2014;103:206 – 217.

2. Cho NH, Shaw JE, Karuranga S, Huang Y, Fernandes JD, Ohlrogge AW,et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. Apr. 2018;138:271-781.

3. Wirth F, Tabone F, Azzopardi L, Gauci M, Adami M, Serracino- Inglott A. Consumer perception of the CPH and community pharmacy services in Malta. Journal of Pharmaceutical Health Services Research. Dec. 2010;1(4):189–194.

4. GDB 2015 SDG Collaborators. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet. Oct 2016;388(10053):1813–1850.

5. 1Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, et al. Novel subgroups of adultonset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–369.

Biography

---

Angela Pizarro is a deputy head pharmacist, specialized in pharmacovigilance systems and regulatory affairs, with nine years of experience in pharmaceutical care. She is a PhD candidate in International Health: Policies and Health and Development in the field of Global Health Solutions on Diabetes. Since 2009 she has developed research at Portuguese and international universities in the areas of pharmacovigilance of drug-interactions, e- health, telemedicine, artificial intelligence in diabetes and policy solutions for global health systems. She a Rotarian.

E-mail: angela.pizarro@ihmt.unl.pt